nodes	percent_of_prediction	percent_of_DWPC	metapath
Rabeprazole—CYP1A1—Clobetasol propionate—psoriasis	0.119	0.169	CbGbCtD
Rabeprazole—CYP1A1—Methoxsalen—psoriasis	0.0623	0.089	CbGbCtD
Rabeprazole—CYP1A2—Clobetasol propionate—psoriasis	0.053	0.0757	CbGbCtD
Rabeprazole—CYP1A1—Cholecalciferol—psoriasis	0.0413	0.0589	CbGbCtD
Rabeprazole—ABCG2—Mycophenolate mofetil—psoriasis	0.0388	0.0554	CbGbCtD
Rabeprazole—ABCG2—Hydrocortisone—psoriasis	0.0311	0.0444	CbGbCtD
Rabeprazole—ABCG2—Cyclosporine—psoriasis	0.0294	0.042	CbGbCtD
Rabeprazole—CYP1A2—Methoxsalen—psoriasis	0.0278	0.0397	CbGbCtD
Rabeprazole—CYP2D6—Hydroxyurea—psoriasis	0.0251	0.0358	CbGbCtD
Rabeprazole—CYP2C19—Cholecalciferol—psoriasis	0.02	0.0285	CbGbCtD
Rabeprazole—ABCG2—Dexamethasone—psoriasis	0.0193	0.0276	CbGbCtD
Rabeprazole—CYP3A4—Calcitriol—psoriasis	0.0187	0.0268	CbGbCtD
Rabeprazole—CYP1A1—Dexamethasone—psoriasis	0.0179	0.0255	CbGbCtD
Rabeprazole—CYP2C9—Cholecalciferol—psoriasis	0.0166	0.0237	CbGbCtD
Rabeprazole—ABCG2—Methotrexate—psoriasis	0.0155	0.0222	CbGbCtD
Rabeprazole—CYP2D6—Cholecalciferol—psoriasis	0.0152	0.0217	CbGbCtD
Rabeprazole—CYP3A4—Methoxsalen—psoriasis	0.0146	0.0208	CbGbCtD
Rabeprazole—CYP2C19—Prednisone—psoriasis	0.0138	0.0198	CbGbCtD
Rabeprazole—CYP2C19—Cyclosporine—psoriasis	0.0131	0.0187	CbGbCtD
Rabeprazole—CYP2C9—Cyclosporine—psoriasis	0.0109	0.0156	CbGbCtD
Rabeprazole—CYP2D6—Cyclosporine—psoriasis	0.00998	0.0143	CbGbCtD
Rabeprazole—CYP3A4—Cholecalciferol—psoriasis	0.00966	0.0138	CbGbCtD
Rabeprazole—CYP2C19—Dexamethasone—psoriasis	0.00864	0.0123	CbGbCtD
Rabeprazole—CYP3A4—Mycophenolate mofetil—psoriasis	0.00837	0.012	CbGbCtD
Rabeprazole—CYP3A4—Triamcinolone—psoriasis	0.00837	0.012	CbGbCtD
Rabeprazole—CYP2C9—Dexamethasone—psoriasis	0.00719	0.0103	CbGbCtD
Rabeprazole—CYP3A4—Betamethasone—psoriasis	0.00718	0.0103	CbGbCtD
Rabeprazole—CYP3A4—Prednisolone—psoriasis	0.00709	0.0101	CbGbCtD
Rabeprazole—CYP3A4—Hydrocortisone—psoriasis	0.00672	0.0096	CbGbCtD
Rabeprazole—CYP3A4—Prednisone—psoriasis	0.00669	0.00956	CbGbCtD
Rabeprazole—CYP2D6—Dexamethasone—psoriasis	0.00657	0.00939	CbGbCtD
Rabeprazole—CYP3A4—Cyclosporine—psoriasis	0.00635	0.00906	CbGbCtD
Rabeprazole—CYP3A4—Dexamethasone—psoriasis	0.00418	0.00597	CbGbCtD
Rabeprazole—CYP2C19—CYP2E1 reactions—CYP2S1—psoriasis	0.000783	0.056	CbGpPWpGaD
Rabeprazole—CYP2D6—CYP2E1 reactions—CYP2S1—psoriasis	0.00072	0.0515	CbGpPWpGaD
Rabeprazole—CYP2C9—CYP2E1 reactions—CYP2S1—psoriasis	0.000714	0.0511	CbGpPWpGaD
Rabeprazole—CYP2D6—Miscellaneous substrates—CYP2S1—psoriasis	0.000672	0.0481	CbGpPWpGaD
Rabeprazole—CYP1A1—Xenobiotics—CYP2S1—psoriasis	0.000593	0.0424	CbGpPWpGaD
Rabeprazole—CYP2C19—Xenobiotics—CYP2S1—psoriasis	0.000485	0.0347	CbGpPWpGaD
Rabeprazole—CYP2D6—Xenobiotics—CYP2S1—psoriasis	0.000446	0.0319	CbGpPWpGaD
Rabeprazole—CYP2C9—Xenobiotics—CYP2S1—psoriasis	0.000442	0.0317	CbGpPWpGaD
Rabeprazole—CYP1A2—Xenobiotics—CYP2S1—psoriasis	0.000378	0.0271	CbGpPWpGaD
Rabeprazole—CYP3A4—Xenobiotics—CYP2S1—psoriasis	0.000292	0.0209	CbGpPWpGaD
Rabeprazole—CYP1A1—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000246	0.0176	CbGpPWpGaD
Rabeprazole—ABCG2—Iron uptake and transport—CP—psoriasis	0.000243	0.0174	CbGpPWpGaD
Rabeprazole—CYP1A1—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000243	0.0174	CbGpPWpGaD
Rabeprazole—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000201	0.0144	CbGpPWpGaD
Rabeprazole—CYP1A1—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.0002	0.0143	CbGpPWpGaD
Rabeprazole—CYP2C19—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000199	0.0142	CbGpPWpGaD
Rabeprazole—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000185	0.0133	CbGpPWpGaD
Rabeprazole—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000184	0.0131	CbGpPWpGaD
Rabeprazole—CYP2D6—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000183	0.0131	CbGpPWpGaD
Rabeprazole—CYP2C9—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000181	0.013	CbGpPWpGaD
Rabeprazole—ABCG2—HIF-1-alpha transcription factor network—CP—psoriasis	0.000173	0.0123	CbGpPWpGaD
Rabeprazole—CYP2C19—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000163	0.0117	CbGpPWpGaD
Rabeprazole—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000157	0.0112	CbGpPWpGaD
Rabeprazole—CYP1A2—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000155	0.0111	CbGpPWpGaD
Rabeprazole—CYP2D6—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.00015	0.0108	CbGpPWpGaD
Rabeprazole—CYP2C9—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000149	0.0107	CbGpPWpGaD
Rabeprazole—ATP4B—Transmembrane transport of small molecules—CP—psoriasis	0.000141	0.0101	CbGpPWpGaD
Rabeprazole—ATP4B—Transmembrane transport of small molecules—CARM1—psoriasis	0.000134	0.00961	CbGpPWpGaD
Rabeprazole—CYP1A1—Oxidative Stress—CAT—psoriasis	0.000129	0.00922	CbGpPWpGaD
Rabeprazole—CYP1A2—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000127	0.00911	CbGpPWpGaD
Rabeprazole—ATP4A—Transmembrane transport of small molecules—CP—psoriasis	0.000125	0.00898	CbGpPWpGaD
Rabeprazole—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000121	0.00867	CbGpPWpGaD
Rabeprazole—CYP1A1—Estrogen Receptor Pathway—JUN—psoriasis	0.000121	0.00864	CbGpPWpGaD
Rabeprazole—ATP4A—Transmembrane transport of small molecules—CARM1—psoriasis	0.00012	0.00856	CbGpPWpGaD
Rabeprazole—CYP3A4—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.00012	0.00856	CbGpPWpGaD
Rabeprazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	0.000118	0.00846	CbGpPWpGaD
Rabeprazole—CYP1A1—Biological oxidations—CYP2S1—psoriasis	0.000106	0.00759	CbGpPWpGaD
Rabeprazole—CYP1A1—Metapathway biotransformation—CYP2S1—psoriasis	0.000105	0.00748	CbGpPWpGaD
Rabeprazole—CYP1A1—Estrogen Receptor Pathway—STAT3—psoriasis	0.000104	0.00747	CbGpPWpGaD
Rabeprazole—CYP1A1—Melatonin metabolism and effects—APOE—psoriasis	0.000103	0.00736	CbGpPWpGaD
Rabeprazole—CYP3A4—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	9.82e-05	0.00703	CbGpPWpGaD
Rabeprazole—CYP3A4—Drug Induction of Bile Acid Pathway—VDR—psoriasis	9.69e-05	0.00693	CbGpPWpGaD
Rabeprazole—CYP1A1—Tryptophan metabolism—CAT—psoriasis	9.15e-05	0.00655	CbGpPWpGaD
Rabeprazole—CYP2C19—Biological oxidations—CYP2S1—psoriasis	8.68e-05	0.00621	CbGpPWpGaD
Rabeprazole—CYP2C19—Metapathway biotransformation—CYP2S1—psoriasis	8.56e-05	0.00612	CbGpPWpGaD
Rabeprazole—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	8.44e-05	0.00604	CbGpPWpGaD
Rabeprazole—CYP2C19—Melatonin metabolism and effects—APOE—psoriasis	8.41e-05	0.00602	CbGpPWpGaD
Rabeprazole—CYP2D6—Biological oxidations—CYP2S1—psoriasis	7.98e-05	0.00571	CbGpPWpGaD
Rabeprazole—CYP2C9—Biological oxidations—CYP2S1—psoriasis	7.91e-05	0.00566	CbGpPWpGaD
Rabeprazole—CYP2D6—Metapathway biotransformation—CYP2S1—psoriasis	7.87e-05	0.00563	CbGpPWpGaD
Rabeprazole—ABCG2—HIF-1-alpha transcription factor network—LEP—psoriasis	7.87e-05	0.00563	CbGpPWpGaD
Rabeprazole—CYP2C9—Metapathway biotransformation—CYP2S1—psoriasis	7.8e-05	0.00558	CbGpPWpGaD
Rabeprazole—CYP2D6—Melatonin metabolism and effects—APOE—psoriasis	7.74e-05	0.00554	CbGpPWpGaD
Rabeprazole—CYP1A2—Estrogen Receptor Pathway—JUN—psoriasis	7.69e-05	0.00551	CbGpPWpGaD
Rabeprazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	7.53e-05	0.00539	CbGpPWpGaD
Rabeprazole—CYP1A1—PPARA activates gene expression—CARM1—psoriasis	7.4e-05	0.0053	CbGpPWpGaD
Rabeprazole—ABCG2—HIF-1-alpha transcription factor network—NOS2—psoriasis	7.33e-05	0.00525	CbGpPWpGaD
Rabeprazole—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CARM1—psoriasis	7.25e-05	0.00519	CbGpPWpGaD
Rabeprazole—ABCG2—HIF-2-alpha transcription factor network—VEGFA—psoriasis	7.22e-05	0.00517	CbGpPWpGaD
Rabeprazole—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	7.21e-05	0.00516	CbGpPWpGaD
Rabeprazole—CYP1A2—Biological oxidations—CYP2S1—psoriasis	6.76e-05	0.00484	CbGpPWpGaD
Rabeprazole—CYP1A2—Metapathway biotransformation—CYP2S1—psoriasis	6.67e-05	0.00477	CbGpPWpGaD
Rabeprazole—CYP1A2—Estrogen Receptor Pathway—STAT3—psoriasis	6.66e-05	0.00476	CbGpPWpGaD
Rabeprazole—CYP1A2—Melatonin metabolism and effects—APOE—psoriasis	6.55e-05	0.00469	CbGpPWpGaD
Rabeprazole—CYP1A1—Melatonin metabolism and effects—NFKB1—psoriasis	6.11e-05	0.00438	CbGpPWpGaD
Rabeprazole—Tachycardia—Triamcinolone—psoriasis	5.97e-05	0.000209	CcSEcCtD
Rabeprazole—CYP1A1—Oxidative Stress—NFKB1—psoriasis	5.95e-05	0.00426	CbGpPWpGaD
Rabeprazole—Malnutrition—Prednisone—psoriasis	5.92e-05	0.000207	CcSEcCtD
Rabeprazole—Erythema—Prednisone—psoriasis	5.92e-05	0.000207	CcSEcCtD
Rabeprazole—Musculoskeletal discomfort—Hydrocortisone—psoriasis	5.91e-05	0.000207	CcSEcCtD
Rabeprazole—Hyperhidrosis—Triamcinolone—psoriasis	5.91e-05	0.000207	CcSEcCtD
Rabeprazole—Agranulocytosis—Methotrexate—psoriasis	5.91e-05	0.000207	CcSEcCtD
Rabeprazole—Convulsion—Betamethasone—psoriasis	5.89e-05	0.000206	CcSEcCtD
Rabeprazole—Convulsion—Dexamethasone—psoriasis	5.89e-05	0.000206	CcSEcCtD
Rabeprazole—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	5.88e-05	0.00421	CbGpPWpGaD
Rabeprazole—Feeling abnormal—Mycophenolate mofetil—psoriasis	5.87e-05	0.000205	CcSEcCtD
Rabeprazole—Insomnia—Hydrocortisone—psoriasis	5.87e-05	0.000205	CcSEcCtD
Rabeprazole—Hypertension—Dexamethasone—psoriasis	5.87e-05	0.000205	CcSEcCtD
Rabeprazole—Hypertension—Betamethasone—psoriasis	5.87e-05	0.000205	CcSEcCtD
Rabeprazole—CYP1A2—Tryptophan metabolism—CAT—psoriasis	5.83e-05	0.00417	CbGpPWpGaD
Rabeprazole—Paraesthesia—Hydrocortisone—psoriasis	5.83e-05	0.000204	CcSEcCtD
Rabeprazole—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	5.83e-05	0.000204	CcSEcCtD
Rabeprazole—Urticaria—Cyclosporine—psoriasis	5.8e-05	0.000203	CcSEcCtD
Rabeprazole—Myalgia—Dexamethasone—psoriasis	5.79e-05	0.000202	CcSEcCtD
Rabeprazole—Myalgia—Betamethasone—psoriasis	5.79e-05	0.000202	CcSEcCtD
Rabeprazole—Body temperature increased—Cyclosporine—psoriasis	5.77e-05	0.000202	CcSEcCtD
Rabeprazole—Abdominal pain—Cyclosporine—psoriasis	5.77e-05	0.000202	CcSEcCtD
Rabeprazole—Anxiety—Dexamethasone—psoriasis	5.77e-05	0.000202	CcSEcCtD
Rabeprazole—Anxiety—Betamethasone—psoriasis	5.77e-05	0.000202	CcSEcCtD
Rabeprazole—Vomiting—Mycophenolic acid—psoriasis	5.74e-05	0.000201	CcSEcCtD
Rabeprazole—Discomfort—Betamethasone—psoriasis	5.72e-05	0.0002	CcSEcCtD
Rabeprazole—Discomfort—Dexamethasone—psoriasis	5.72e-05	0.0002	CcSEcCtD
Rabeprazole—Dyspepsia—Hydrocortisone—psoriasis	5.71e-05	0.0002	CcSEcCtD
Rabeprazole—Rash—Mycophenolic acid—psoriasis	5.69e-05	0.000199	CcSEcCtD
Rabeprazole—Dermatitis—Mycophenolic acid—psoriasis	5.69e-05	0.000199	CcSEcCtD
Rabeprazole—Pain—Prednisolone—psoriasis	5.68e-05	0.000199	CcSEcCtD
Rabeprazole—Hepatitis—Methotrexate—psoriasis	5.68e-05	0.000199	CcSEcCtD
Rabeprazole—Urticaria—Mycophenolate mofetil—psoriasis	5.66e-05	0.000198	CcSEcCtD
Rabeprazole—Headache—Mycophenolic acid—psoriasis	5.66e-05	0.000198	CcSEcCtD
Rabeprazole—Decreased appetite—Hydrocortisone—psoriasis	5.64e-05	0.000197	CcSEcCtD
Rabeprazole—Pharyngitis—Methotrexate—psoriasis	5.64e-05	0.000197	CcSEcCtD
Rabeprazole—Abdominal pain—Mycophenolate mofetil—psoriasis	5.63e-05	0.000197	CcSEcCtD
Rabeprazole—Body temperature increased—Mycophenolate mofetil—psoriasis	5.63e-05	0.000197	CcSEcCtD
Rabeprazole—Urinary tract disorder—Methotrexate—psoriasis	5.61e-05	0.000196	CcSEcCtD
Rabeprazole—ABCG2—Fluoropyrimidine Activity—TP53—psoriasis	5.58e-05	0.004	CbGpPWpGaD
Rabeprazole—Vision blurred—Prednisone—psoriasis	5.58e-05	0.000195	CcSEcCtD
Rabeprazole—Urethral disorder—Methotrexate—psoriasis	5.57e-05	0.000195	CcSEcCtD
Rabeprazole—Musculoskeletal discomfort—Triamcinolone—psoriasis	5.57e-05	0.000195	CcSEcCtD
Rabeprazole—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	5.56e-05	0.00398	CbGpPWpGaD
Rabeprazole—Pain—Hydrocortisone—psoriasis	5.55e-05	0.000194	CcSEcCtD
Rabeprazole—Oedema—Dexamethasone—psoriasis	5.55e-05	0.000194	CcSEcCtD
Rabeprazole—Anaphylactic shock—Dexamethasone—psoriasis	5.55e-05	0.000194	CcSEcCtD
Rabeprazole—Anaphylactic shock—Betamethasone—psoriasis	5.55e-05	0.000194	CcSEcCtD
Rabeprazole—Oedema—Betamethasone—psoriasis	5.55e-05	0.000194	CcSEcCtD
Rabeprazole—Insomnia—Triamcinolone—psoriasis	5.53e-05	0.000193	CcSEcCtD
Rabeprazole—Ill-defined disorder—Prednisone—psoriasis	5.49e-05	0.000192	CcSEcCtD
Rabeprazole—Paraesthesia—Triamcinolone—psoriasis	5.49e-05	0.000192	CcSEcCtD
Rabeprazole—Feeling abnormal—Prednisolone—psoriasis	5.48e-05	0.000192	CcSEcCtD
Rabeprazole—Visual impairment—Methotrexate—psoriasis	5.48e-05	0.000192	CcSEcCtD
Rabeprazole—Anaemia—Prednisone—psoriasis	5.47e-05	0.000191	CcSEcCtD
Rabeprazole—Shock—Dexamethasone—psoriasis	5.46e-05	0.000191	CcSEcCtD
Rabeprazole—Shock—Betamethasone—psoriasis	5.46e-05	0.000191	CcSEcCtD
Rabeprazole—Dyspnoea—Triamcinolone—psoriasis	5.45e-05	0.000191	CcSEcCtD
Rabeprazole—Agitation—Prednisone—psoriasis	5.44e-05	0.00019	CcSEcCtD
Rabeprazole—Thrombocytopenia—Dexamethasone—psoriasis	5.43e-05	0.00019	CcSEcCtD
Rabeprazole—Thrombocytopenia—Betamethasone—psoriasis	5.43e-05	0.00019	CcSEcCtD
Rabeprazole—Tachycardia—Betamethasone—psoriasis	5.41e-05	0.000189	CcSEcCtD
Rabeprazole—Tachycardia—Dexamethasone—psoriasis	5.41e-05	0.000189	CcSEcCtD
Rabeprazole—Angioedema—Prednisone—psoriasis	5.41e-05	0.000189	CcSEcCtD
Rabeprazole—Hypersensitivity—Cyclosporine—psoriasis	5.38e-05	0.000188	CcSEcCtD
Rabeprazole—Dyspepsia—Triamcinolone—psoriasis	5.38e-05	0.000188	CcSEcCtD
Rabeprazole—Erythema multiforme—Methotrexate—psoriasis	5.37e-05	0.000188	CcSEcCtD
Rabeprazole—Nausea—Mycophenolic acid—psoriasis	5.36e-05	0.000188	CcSEcCtD
Rabeprazole—Hyperhidrosis—Betamethasone—psoriasis	5.36e-05	0.000188	CcSEcCtD
Rabeprazole—Hyperhidrosis—Dexamethasone—psoriasis	5.36e-05	0.000188	CcSEcCtD
Rabeprazole—Feeling abnormal—Hydrocortisone—psoriasis	5.35e-05	0.000187	CcSEcCtD
Rabeprazole—Malaise—Prednisone—psoriasis	5.34e-05	0.000187	CcSEcCtD
Rabeprazole—Vertigo—Prednisone—psoriasis	5.32e-05	0.000186	CcSEcCtD
Rabeprazole—Eye disorder—Methotrexate—psoriasis	5.31e-05	0.000186	CcSEcCtD
Rabeprazole—Gastrointestinal pain—Hydrocortisone—psoriasis	5.31e-05	0.000186	CcSEcCtD
Rabeprazole—Syncope—Prednisone—psoriasis	5.31e-05	0.000186	CcSEcCtD
Rabeprazole—Tinnitus—Methotrexate—psoriasis	5.3e-05	0.000185	CcSEcCtD
Rabeprazole—Anorexia—Betamethasone—psoriasis	5.29e-05	0.000185	CcSEcCtD
Rabeprazole—Anorexia—Dexamethasone—psoriasis	5.29e-05	0.000185	CcSEcCtD
Rabeprazole—Urticaria—Prednisolone—psoriasis	5.28e-05	0.000185	CcSEcCtD
Rabeprazole—Hypersensitivity—Mycophenolate mofetil—psoriasis	5.25e-05	0.000184	CcSEcCtD
Rabeprazole—Asthenia—Cyclosporine—psoriasis	5.24e-05	0.000183	CcSEcCtD
Rabeprazole—Pain—Triamcinolone—psoriasis	5.23e-05	0.000183	CcSEcCtD
Rabeprazole—CYP3A4—Biological oxidations—CYP2S1—psoriasis	5.22e-05	0.00373	CbGpPWpGaD
Rabeprazole—Loss of consciousness—Prednisone—psoriasis	5.2e-05	0.000182	CcSEcCtD
Rabeprazole—Hypotension—Betamethasone—psoriasis	5.18e-05	0.000181	CcSEcCtD
Rabeprazole—Hypotension—Dexamethasone—psoriasis	5.18e-05	0.000181	CcSEcCtD
Rabeprazole—Pruritus—Cyclosporine—psoriasis	5.17e-05	0.000181	CcSEcCtD
Rabeprazole—Urticaria—Hydrocortisone—psoriasis	5.16e-05	0.00018	CcSEcCtD
Rabeprazole—Angiopathy—Methotrexate—psoriasis	5.16e-05	0.00018	CcSEcCtD
Rabeprazole—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	5.15e-05	0.00368	CbGpPWpGaD
Rabeprazole—Abdominal pain—Hydrocortisone—psoriasis	5.13e-05	0.00018	CcSEcCtD
Rabeprazole—Body temperature increased—Hydrocortisone—psoriasis	5.13e-05	0.00018	CcSEcCtD
Rabeprazole—Convulsion—Prednisone—psoriasis	5.13e-05	0.000179	CcSEcCtD
Rabeprazole—Asthenia—Mycophenolate mofetil—psoriasis	5.11e-05	0.000179	CcSEcCtD
Rabeprazole—Hypertension—Prednisone—psoriasis	5.11e-05	0.000179	CcSEcCtD
Rabeprazole—Chills—Methotrexate—psoriasis	5.1e-05	0.000178	CcSEcCtD
Rabeprazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	5.08e-05	0.00364	CbGpPWpGaD
Rabeprazole—Musculoskeletal discomfort—Dexamethasone—psoriasis	5.05e-05	0.000177	CcSEcCtD
Rabeprazole—Musculoskeletal discomfort—Betamethasone—psoriasis	5.05e-05	0.000177	CcSEcCtD
Rabeprazole—Pruritus—Mycophenolate mofetil—psoriasis	5.04e-05	0.000176	CcSEcCtD
Rabeprazole—Myalgia—Prednisone—psoriasis	5.04e-05	0.000176	CcSEcCtD
Rabeprazole—Arthralgia—Prednisone—psoriasis	5.04e-05	0.000176	CcSEcCtD
Rabeprazole—Feeling abnormal—Triamcinolone—psoriasis	5.04e-05	0.000176	CcSEcCtD
Rabeprazole—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	5.03e-05	0.0036	CbGpPWpGaD
Rabeprazole—Anxiety—Prednisone—psoriasis	5.02e-05	0.000176	CcSEcCtD
Rabeprazole—Alopecia—Methotrexate—psoriasis	5.02e-05	0.000176	CcSEcCtD
Rabeprazole—Insomnia—Dexamethasone—psoriasis	5.02e-05	0.000175	CcSEcCtD
Rabeprazole—Insomnia—Betamethasone—psoriasis	5.02e-05	0.000175	CcSEcCtD
Rabeprazole—CYP2C19—Melatonin metabolism and effects—NFKB1—psoriasis	5e-05	0.00358	CbGpPWpGaD
Rabeprazole—Diarrhoea—Cyclosporine—psoriasis	5e-05	0.000175	CcSEcCtD
Rabeprazole—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—CARM1—psoriasis	4.99e-05	0.00357	CbGpPWpGaD
Rabeprazole—Paraesthesia—Betamethasone—psoriasis	4.98e-05	0.000174	CcSEcCtD
Rabeprazole—Paraesthesia—Dexamethasone—psoriasis	4.98e-05	0.000174	CcSEcCtD
Rabeprazole—Discomfort—Prednisone—psoriasis	4.98e-05	0.000174	CcSEcCtD
Rabeprazole—Malnutrition—Methotrexate—psoriasis	4.95e-05	0.000173	CcSEcCtD
Rabeprazole—Erythema—Methotrexate—psoriasis	4.95e-05	0.000173	CcSEcCtD
Rabeprazole—Hypersensitivity—Prednisolone—psoriasis	4.9e-05	0.000171	CcSEcCtD
Rabeprazole—Dyspepsia—Dexamethasone—psoriasis	4.88e-05	0.000171	CcSEcCtD
Rabeprazole—Dyspepsia—Betamethasone—psoriasis	4.88e-05	0.000171	CcSEcCtD
Rabeprazole—Diarrhoea—Mycophenolate mofetil—psoriasis	4.88e-05	0.000171	CcSEcCtD
Rabeprazole—ABCG2—HIF-1-alpha transcription factor network—JUN—psoriasis	4.86e-05	0.00348	CbGpPWpGaD
Rabeprazole—Urticaria—Triamcinolone—psoriasis	4.86e-05	0.00017	CcSEcCtD
Rabeprazole—Dysgeusia—Methotrexate—psoriasis	4.84e-05	0.000169	CcSEcCtD
Rabeprazole—Body temperature increased—Triamcinolone—psoriasis	4.83e-05	0.000169	CcSEcCtD
Rabeprazole—Dizziness—Cyclosporine—psoriasis	4.83e-05	0.000169	CcSEcCtD
Rabeprazole—Oedema—Prednisone—psoriasis	4.83e-05	0.000169	CcSEcCtD
Rabeprazole—Anaphylactic shock—Prednisone—psoriasis	4.83e-05	0.000169	CcSEcCtD
Rabeprazole—Decreased appetite—Dexamethasone—psoriasis	4.82e-05	0.000169	CcSEcCtD
Rabeprazole—Decreased appetite—Betamethasone—psoriasis	4.82e-05	0.000169	CcSEcCtD
Rabeprazole—Back pain—Methotrexate—psoriasis	4.78e-05	0.000167	CcSEcCtD
Rabeprazole—Hypersensitivity—Hydrocortisone—psoriasis	4.78e-05	0.000167	CcSEcCtD
Rabeprazole—Shock—Prednisone—psoriasis	4.75e-05	0.000166	CcSEcCtD
Rabeprazole—Pain—Betamethasone—psoriasis	4.74e-05	0.000166	CcSEcCtD
Rabeprazole—Pain—Dexamethasone—psoriasis	4.74e-05	0.000166	CcSEcCtD
Rabeprazole—Tachycardia—Prednisone—psoriasis	4.71e-05	0.000165	CcSEcCtD
Rabeprazole—Dizziness—Mycophenolate mofetil—psoriasis	4.71e-05	0.000165	CcSEcCtD
Rabeprazole—Hyperhidrosis—Prednisone—psoriasis	4.67e-05	0.000163	CcSEcCtD
Rabeprazole—Vision blurred—Methotrexate—psoriasis	4.66e-05	0.000163	CcSEcCtD
Rabeprazole—Asthenia—Hydrocortisone—psoriasis	4.66e-05	0.000163	CcSEcCtD
Rabeprazole—Vomiting—Cyclosporine—psoriasis	4.64e-05	0.000162	CcSEcCtD
Rabeprazole—Rash—Cyclosporine—psoriasis	4.61e-05	0.000161	CcSEcCtD
Rabeprazole—Anorexia—Prednisone—psoriasis	4.6e-05	0.000161	CcSEcCtD
Rabeprazole—Dermatitis—Cyclosporine—psoriasis	4.6e-05	0.000161	CcSEcCtD
Rabeprazole—CYP2D6—Melatonin metabolism and effects—NFKB1—psoriasis	4.6e-05	0.00329	CbGpPWpGaD
Rabeprazole—Pruritus—Hydrocortisone—psoriasis	4.59e-05	0.000161	CcSEcCtD
Rabeprazole—Ill-defined disorder—Methotrexate—psoriasis	4.59e-05	0.000161	CcSEcCtD
Rabeprazole—Headache—Cyclosporine—psoriasis	4.58e-05	0.00016	CcSEcCtD
Rabeprazole—Anaemia—Methotrexate—psoriasis	4.57e-05	0.00016	CcSEcCtD
Rabeprazole—Feeling abnormal—Betamethasone—psoriasis	4.57e-05	0.00016	CcSEcCtD
Rabeprazole—Feeling abnormal—Dexamethasone—psoriasis	4.57e-05	0.00016	CcSEcCtD
Rabeprazole—Gastrointestinal pain—Betamethasone—psoriasis	4.54e-05	0.000159	CcSEcCtD
Rabeprazole—Gastrointestinal pain—Dexamethasone—psoriasis	4.54e-05	0.000159	CcSEcCtD
Rabeprazole—Vomiting—Mycophenolate mofetil—psoriasis	4.53e-05	0.000158	CcSEcCtD
Rabeprazole—Hypersensitivity—Triamcinolone—psoriasis	4.5e-05	0.000158	CcSEcCtD
Rabeprazole—CYP3A4—Tryptophan metabolism—CAT—psoriasis	4.5e-05	0.00322	CbGpPWpGaD
Rabeprazole—Rash—Mycophenolate mofetil—psoriasis	4.49e-05	0.000157	CcSEcCtD
Rabeprazole—Dermatitis—Mycophenolate mofetil—psoriasis	4.49e-05	0.000157	CcSEcCtD
Rabeprazole—Headache—Mycophenolate mofetil—psoriasis	4.46e-05	0.000156	CcSEcCtD
Rabeprazole—Malaise—Methotrexate—psoriasis	4.46e-05	0.000156	CcSEcCtD
Rabeprazole—Vertigo—Methotrexate—psoriasis	4.44e-05	0.000155	CcSEcCtD
Rabeprazole—Diarrhoea—Hydrocortisone—psoriasis	4.44e-05	0.000155	CcSEcCtD
Rabeprazole—Leukopenia—Methotrexate—psoriasis	4.43e-05	0.000155	CcSEcCtD
Rabeprazole—Urticaria—Dexamethasone—psoriasis	4.41e-05	0.000154	CcSEcCtD
Rabeprazole—Urticaria—Betamethasone—psoriasis	4.41e-05	0.000154	CcSEcCtD
Rabeprazole—Musculoskeletal discomfort—Prednisone—psoriasis	4.4e-05	0.000154	CcSEcCtD
Rabeprazole—Dizziness—Prednisolone—psoriasis	4.4e-05	0.000154	CcSEcCtD
Rabeprazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	4.39e-05	0.00314	CbGpPWpGaD
Rabeprazole—Asthenia—Triamcinolone—psoriasis	4.39e-05	0.000153	CcSEcCtD
Rabeprazole—Body temperature increased—Betamethasone—psoriasis	4.38e-05	0.000153	CcSEcCtD
Rabeprazole—Body temperature increased—Dexamethasone—psoriasis	4.38e-05	0.000153	CcSEcCtD
Rabeprazole—Abdominal pain—Dexamethasone—psoriasis	4.38e-05	0.000153	CcSEcCtD
Rabeprazole—Abdominal pain—Betamethasone—psoriasis	4.38e-05	0.000153	CcSEcCtD
Rabeprazole—Insomnia—Prednisone—psoriasis	4.37e-05	0.000153	CcSEcCtD
Rabeprazole—Nausea—Cyclosporine—psoriasis	4.34e-05	0.000152	CcSEcCtD
Rabeprazole—Paraesthesia—Prednisone—psoriasis	4.34e-05	0.000152	CcSEcCtD
Rabeprazole—Pruritus—Triamcinolone—psoriasis	4.32e-05	0.000151	CcSEcCtD
Rabeprazole—Cough—Methotrexate—psoriasis	4.32e-05	0.000151	CcSEcCtD
Rabeprazole—Dizziness—Hydrocortisone—psoriasis	4.29e-05	0.00015	CcSEcCtD
Rabeprazole—Convulsion—Methotrexate—psoriasis	4.29e-05	0.00015	CcSEcCtD
Rabeprazole—Dyspepsia—Prednisone—psoriasis	4.25e-05	0.000149	CcSEcCtD
Rabeprazole—ABCG2—HIF-1-alpha transcription factor network—VEGFA—psoriasis	4.25e-05	0.00304	CbGpPWpGaD
Rabeprazole—Nausea—Mycophenolate mofetil—psoriasis	4.23e-05	0.000148	CcSEcCtD
Rabeprazole—CYP1A1—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	4.23e-05	0.00302	CbGpPWpGaD
Rabeprazole—Myalgia—Methotrexate—psoriasis	4.21e-05	0.000147	CcSEcCtD
Rabeprazole—Arthralgia—Methotrexate—psoriasis	4.21e-05	0.000147	CcSEcCtD
Rabeprazole—Chest pain—Methotrexate—psoriasis	4.21e-05	0.000147	CcSEcCtD
Rabeprazole—Decreased appetite—Prednisone—psoriasis	4.2e-05	0.000147	CcSEcCtD
Rabeprazole—Rash—Prednisolone—psoriasis	4.19e-05	0.000147	CcSEcCtD
Rabeprazole—Dermatitis—Prednisolone—psoriasis	4.19e-05	0.000146	CcSEcCtD
Rabeprazole—Headache—Prednisolone—psoriasis	4.16e-05	0.000146	CcSEcCtD
Rabeprazole—Discomfort—Methotrexate—psoriasis	4.16e-05	0.000146	CcSEcCtD
Rabeprazole—Constipation—Prednisone—psoriasis	4.13e-05	0.000144	CcSEcCtD
Rabeprazole—Vomiting—Hydrocortisone—psoriasis	4.13e-05	0.000144	CcSEcCtD
Rabeprazole—Rash—Hydrocortisone—psoriasis	4.09e-05	0.000143	CcSEcCtD
Rabeprazole—Dermatitis—Hydrocortisone—psoriasis	4.09e-05	0.000143	CcSEcCtD
Rabeprazole—Confusional state—Methotrexate—psoriasis	4.07e-05	0.000142	CcSEcCtD
Rabeprazole—Headache—Hydrocortisone—psoriasis	4.07e-05	0.000142	CcSEcCtD
Rabeprazole—Dizziness—Triamcinolone—psoriasis	4.04e-05	0.000141	CcSEcCtD
Rabeprazole—Anaphylactic shock—Methotrexate—psoriasis	4.04e-05	0.000141	CcSEcCtD
Rabeprazole—Feeling abnormal—Prednisone—psoriasis	3.98e-05	0.000139	CcSEcCtD
Rabeprazole—Asthenia—Betamethasone—psoriasis	3.98e-05	0.000139	CcSEcCtD
Rabeprazole—Asthenia—Dexamethasone—psoriasis	3.98e-05	0.000139	CcSEcCtD
Rabeprazole—Thrombocytopenia—Methotrexate—psoriasis	3.95e-05	0.000138	CcSEcCtD
Rabeprazole—Gastrointestinal pain—Prednisone—psoriasis	3.95e-05	0.000138	CcSEcCtD
Rabeprazole—Nausea—Prednisolone—psoriasis	3.95e-05	0.000138	CcSEcCtD
Rabeprazole—Pruritus—Dexamethasone—psoriasis	3.92e-05	0.000137	CcSEcCtD
Rabeprazole—Pruritus—Betamethasone—psoriasis	3.92e-05	0.000137	CcSEcCtD
Rabeprazole—Hyperhidrosis—Methotrexate—psoriasis	3.9e-05	0.000137	CcSEcCtD
Rabeprazole—CYP1A2—Melatonin metabolism and effects—NFKB1—psoriasis	3.9e-05	0.00279	CbGpPWpGaD
Rabeprazole—Vomiting—Triamcinolone—psoriasis	3.89e-05	0.000136	CcSEcCtD
Rabeprazole—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	3.88e-05	0.00278	CbGpPWpGaD
Rabeprazole—Nausea—Hydrocortisone—psoriasis	3.86e-05	0.000135	CcSEcCtD
Rabeprazole—Rash—Triamcinolone—psoriasis	3.85e-05	0.000135	CcSEcCtD
Rabeprazole—Dermatitis—Triamcinolone—psoriasis	3.85e-05	0.000135	CcSEcCtD
Rabeprazole—Anorexia—Methotrexate—psoriasis	3.85e-05	0.000135	CcSEcCtD
Rabeprazole—Urticaria—Prednisone—psoriasis	3.84e-05	0.000134	CcSEcCtD
Rabeprazole—CYP1A1—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	3.84e-05	0.00275	CbGpPWpGaD
Rabeprazole—Headache—Triamcinolone—psoriasis	3.83e-05	0.000134	CcSEcCtD
Rabeprazole—Abdominal pain—Prednisone—psoriasis	3.82e-05	0.000134	CcSEcCtD
Rabeprazole—Body temperature increased—Prednisone—psoriasis	3.82e-05	0.000134	CcSEcCtD
Rabeprazole—Diarrhoea—Betamethasone—psoriasis	3.79e-05	0.000133	CcSEcCtD
Rabeprazole—Diarrhoea—Dexamethasone—psoriasis	3.79e-05	0.000133	CcSEcCtD
Rabeprazole—Hypotension—Methotrexate—psoriasis	3.77e-05	0.000132	CcSEcCtD
Rabeprazole—Musculoskeletal discomfort—Methotrexate—psoriasis	3.68e-05	0.000129	CcSEcCtD
Rabeprazole—Dizziness—Dexamethasone—psoriasis	3.67e-05	0.000128	CcSEcCtD
Rabeprazole—Dizziness—Betamethasone—psoriasis	3.67e-05	0.000128	CcSEcCtD
Rabeprazole—Insomnia—Methotrexate—psoriasis	3.65e-05	0.000128	CcSEcCtD
Rabeprazole—Nausea—Triamcinolone—psoriasis	3.63e-05	0.000127	CcSEcCtD
Rabeprazole—Paraesthesia—Methotrexate—psoriasis	3.62e-05	0.000127	CcSEcCtD
Rabeprazole—Dyspnoea—Methotrexate—psoriasis	3.6e-05	0.000126	CcSEcCtD
Rabeprazole—Somnolence—Methotrexate—psoriasis	3.59e-05	0.000126	CcSEcCtD
Rabeprazole—Hypersensitivity—Prednisone—psoriasis	3.56e-05	0.000124	CcSEcCtD
Rabeprazole—Dyspepsia—Methotrexate—psoriasis	3.55e-05	0.000124	CcSEcCtD
Rabeprazole—Vomiting—Dexamethasone—psoriasis	3.53e-05	0.000123	CcSEcCtD
Rabeprazole—Vomiting—Betamethasone—psoriasis	3.53e-05	0.000123	CcSEcCtD
Rabeprazole—Decreased appetite—Methotrexate—psoriasis	3.51e-05	0.000123	CcSEcCtD
Rabeprazole—Rash—Betamethasone—psoriasis	3.5e-05	0.000122	CcSEcCtD
Rabeprazole—Rash—Dexamethasone—psoriasis	3.5e-05	0.000122	CcSEcCtD
Rabeprazole—Dermatitis—Dexamethasone—psoriasis	3.49e-05	0.000122	CcSEcCtD
Rabeprazole—Dermatitis—Betamethasone—psoriasis	3.49e-05	0.000122	CcSEcCtD
Rabeprazole—Headache—Dexamethasone—psoriasis	3.47e-05	0.000122	CcSEcCtD
Rabeprazole—Headache—Betamethasone—psoriasis	3.47e-05	0.000122	CcSEcCtD
Rabeprazole—Asthenia—Prednisone—psoriasis	3.47e-05	0.000121	CcSEcCtD
Rabeprazole—Pain—Methotrexate—psoriasis	3.45e-05	0.000121	CcSEcCtD
Rabeprazole—Pruritus—Prednisone—psoriasis	3.42e-05	0.00012	CcSEcCtD
Rabeprazole—Feeling abnormal—Methotrexate—psoriasis	3.33e-05	0.000116	CcSEcCtD
Rabeprazole—Diarrhoea—Prednisone—psoriasis	3.3e-05	0.000116	CcSEcCtD
Rabeprazole—Gastrointestinal pain—Methotrexate—psoriasis	3.3e-05	0.000115	CcSEcCtD
Rabeprazole—Nausea—Dexamethasone—psoriasis	3.29e-05	0.000115	CcSEcCtD
Rabeprazole—Nausea—Betamethasone—psoriasis	3.29e-05	0.000115	CcSEcCtD
Rabeprazole—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	3.29e-05	0.00235	CbGpPWpGaD
Rabeprazole—CYP1A1—Aryl Hydrocarbon Receptor—TNF—psoriasis	3.29e-05	0.00235	CbGpPWpGaD
Rabeprazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	3.24e-05	0.00232	CbGpPWpGaD
Rabeprazole—Urticaria—Methotrexate—psoriasis	3.21e-05	0.000112	CcSEcCtD
Rabeprazole—Dizziness—Prednisone—psoriasis	3.19e-05	0.000112	CcSEcCtD
Rabeprazole—Body temperature increased—Methotrexate—psoriasis	3.19e-05	0.000112	CcSEcCtD
Rabeprazole—Abdominal pain—Methotrexate—psoriasis	3.19e-05	0.000112	CcSEcCtD
Rabeprazole—ABCG2—Metabolism—NDUFA5—psoriasis	3.15e-05	0.00225	CbGpPWpGaD
Rabeprazole—CYP1A1—PPARA activates gene expression—PPARG—psoriasis	3.08e-05	0.00221	CbGpPWpGaD
Rabeprazole—Vomiting—Prednisone—psoriasis	3.07e-05	0.000107	CcSEcCtD
Rabeprazole—Rash—Prednisone—psoriasis	3.05e-05	0.000107	CcSEcCtD
Rabeprazole—Dermatitis—Prednisone—psoriasis	3.04e-05	0.000106	CcSEcCtD
Rabeprazole—Headache—Prednisone—psoriasis	3.03e-05	0.000106	CcSEcCtD
Rabeprazole—CYP1A1—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—psoriasis	3.02e-05	0.00216	CbGpPWpGaD
Rabeprazole—Hypersensitivity—Methotrexate—psoriasis	2.97e-05	0.000104	CcSEcCtD
Rabeprazole—ABCG2—Transmembrane transport of small molecules—CP—psoriasis	2.93e-05	0.0021	CbGpPWpGaD
Rabeprazole—Asthenia—Methotrexate—psoriasis	2.9e-05	0.000101	CcSEcCtD
Rabeprazole—Nausea—Prednisone—psoriasis	2.87e-05	0.0001	CcSEcCtD
Rabeprazole—Pruritus—Methotrexate—psoriasis	2.86e-05	9.99e-05	CcSEcCtD
Rabeprazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	2.8e-05	0.002	CbGpPWpGaD
Rabeprazole—ABCG2—Transmembrane transport of small molecules—CARM1—psoriasis	2.79e-05	0.002	CbGpPWpGaD
Rabeprazole—Diarrhoea—Methotrexate—psoriasis	2.76e-05	9.66e-05	CcSEcCtD
Rabeprazole—CYP1A2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	2.69e-05	0.00193	CbGpPWpGaD
Rabeprazole—ABCG2—Metabolism—CYP2S1—psoriasis	2.68e-05	0.00192	CbGpPWpGaD
Rabeprazole—Dizziness—Methotrexate—psoriasis	2.67e-05	9.34e-05	CcSEcCtD
Rabeprazole—Vomiting—Methotrexate—psoriasis	2.57e-05	8.98e-05	CcSEcCtD
Rabeprazole—Rash—Methotrexate—psoriasis	2.55e-05	8.9e-05	CcSEcCtD
Rabeprazole—Dermatitis—Methotrexate—psoriasis	2.54e-05	8.89e-05	CcSEcCtD
Rabeprazole—Headache—Methotrexate—psoriasis	2.53e-05	8.85e-05	CcSEcCtD
Rabeprazole—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	2.45e-05	0.00175	CbGpPWpGaD
Rabeprazole—Nausea—Methotrexate—psoriasis	2.4e-05	8.39e-05	CcSEcCtD
Rabeprazole—CYP1A1—Metabolism—NDUFA5—psoriasis	2.13e-05	0.00153	CbGpPWpGaD
Rabeprazole—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	2.1e-05	0.0015	CbGpPWpGaD
Rabeprazole—CYP1A2—Aryl Hydrocarbon Receptor—TNF—psoriasis	2.1e-05	0.0015	CbGpPWpGaD
Rabeprazole—CYP1A1—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—psoriasis	2.08e-05	0.00149	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.99e-05	0.00142	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism—CYP2S1—psoriasis	1.81e-05	0.0013	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism—NDUFA5—psoriasis	1.74e-05	0.00125	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.63e-05	0.00116	CbGpPWpGaD
Rabeprazole—CYP2D6—Metabolism—NDUFA5—psoriasis	1.6e-05	0.00115	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism—NDUFA5—psoriasis	1.59e-05	0.00114	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism—CYP2S1—psoriasis	1.48e-05	0.00106	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.48e-05	0.00106	CbGpPWpGaD
Rabeprazole—CYP2D6—Metabolism—CYP2S1—psoriasis	1.36e-05	0.000977	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism—NDUFA5—psoriasis	1.36e-05	0.000973	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism—CYP2S1—psoriasis	1.35e-05	0.000968	CbGpPWpGaD
Rabeprazole—ABCG2—Metabolism—CARM1—psoriasis	1.31e-05	0.000936	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.27e-05	0.000907	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism—CYP2S1—psoriasis	1.16e-05	0.000827	CbGpPWpGaD
Rabeprazole—CYP3A4—Metabolism—NDUFA5—psoriasis	1.05e-05	0.000751	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism of lipids and lipoproteins—APOE—psoriasis	9.5e-06	0.00068	CbGpPWpGaD
Rabeprazole—CYP3A4—Metabolism—CYP2S1—psoriasis	8.92e-06	0.000639	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism—CARM1—psoriasis	8.85e-06	0.000634	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism of lipids and lipoproteins—PPARG—psoriasis	8.28e-06	0.000592	CbGpPWpGaD
Rabeprazole—ABCG2—Metabolism—CAT—psoriasis	8.05e-06	0.000576	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	7.78e-06	0.000557	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism—CARM1—psoriasis	7.25e-06	0.000519	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	7.09e-06	0.000507	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	6.77e-06	0.000485	CbGpPWpGaD
Rabeprazole—CYP2D6—Metabolism—CARM1—psoriasis	6.66e-06	0.000477	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism—CARM1—psoriasis	6.61e-06	0.000473	CbGpPWpGaD
Rabeprazole—ABCG2—Metabolism—APOE—psoriasis	6.25e-06	0.000447	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	6.18e-06	0.000442	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	6.06e-06	0.000434	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism—CARM1—psoriasis	5.65e-06	0.000404	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism—CAT—psoriasis	5.45e-06	0.00039	CbGpPWpGaD
Rabeprazole—ABCG2—Metabolism—PPARG—psoriasis	5.45e-06	0.00039	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	5.28e-06	0.000378	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism—CAT—psoriasis	4.46e-06	0.000319	CbGpPWpGaD
Rabeprazole—CYP3A4—Metabolism—CARM1—psoriasis	4.36e-06	0.000312	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism—APOE—psoriasis	4.23e-06	0.000303	CbGpPWpGaD
Rabeprazole—CYP2D6—Metabolism—CAT—psoriasis	4.1e-06	0.000293	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism—CAT—psoriasis	4.06e-06	0.000291	CbGpPWpGaD
Rabeprazole—CYP1A1—Metabolism—PPARG—psoriasis	3.69e-06	0.000264	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism—CAT—psoriasis	3.47e-06	0.000249	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism—APOE—psoriasis	3.46e-06	0.000248	CbGpPWpGaD
Rabeprazole—CYP2D6—Metabolism—APOE—psoriasis	3.18e-06	0.000228	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism—APOE—psoriasis	3.16e-06	0.000226	CbGpPWpGaD
Rabeprazole—CYP2C19—Metabolism—PPARG—psoriasis	3.02e-06	0.000216	CbGpPWpGaD
Rabeprazole—CYP2D6—Metabolism—PPARG—psoriasis	2.77e-06	0.000199	CbGpPWpGaD
Rabeprazole—CYP2C9—Metabolism—PPARG—psoriasis	2.75e-06	0.000197	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism—APOE—psoriasis	2.7e-06	0.000193	CbGpPWpGaD
Rabeprazole—CYP3A4—Metabolism—CAT—psoriasis	2.68e-06	0.000192	CbGpPWpGaD
Rabeprazole—CYP1A2—Metabolism—PPARG—psoriasis	2.35e-06	0.000168	CbGpPWpGaD
Rabeprazole—CYP3A4—Metabolism—APOE—psoriasis	2.08e-06	0.000149	CbGpPWpGaD
Rabeprazole—CYP3A4—Metabolism—PPARG—psoriasis	1.81e-06	0.00013	CbGpPWpGaD
